Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Solomon Islands Health Reporter.
Press releases published on July 8, 2025
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment
GlobeNewswire
·
July 8, 2025
SEATTLE, July 08, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (OTC: FITY), a Nevada-based pioneer in AI-driven drug repurposing and AI-driven functional medicine, today unveiled a transformative Game Plan to achieve a $50 million valuation and …
SlimJaro Botanical Approaches Gain Interest in 2025 for Inflammation-Related Metabolic Wellness
GlobeNewswire
·
July 8, 2025
New York City, NY, July 08, 2025 (GLOBE NEWSWIRE) -- SlimJaro Introduced as a Gentle Formulation Aimed at Inflammation Linked Weight Challenges: In 2025, health conversations surrounding weight loss have increasingly focused on the role of chronic …
Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
GlobeNewswire
·
July 8, 2025
Operational and Financial Flexibility Enhanced Through New Credit Facility Second Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or …
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire
·
July 8, 2025
ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord …
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
GlobeNewswire
·
July 8, 2025
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has …
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
GlobeNewswire
·
July 8, 2025
DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been …
Certara Announces Expansion of Clinical Technology Collaboration with Merck
GlobeNewswire
·
July 8, 2025
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use …
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
GlobeNewswire
·
July 8, 2025
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …
Vaxart Announces Trading on OTCQX Best Market
GlobeNewswire
·
July 8, 2025
SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, …
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire
·
July 8, 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, …
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
GlobeNewswire
·
July 8, 2025
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint …
BD² AND BRAIN CANADA ANNOUNCE PARTNERSHIP AND NEW INTERNATIONAL SITE TO JOIN LANDMARK BIPOLAR DISORDER RESEARCH NETWORK
GlobeNewswire
·
July 8, 2025
Washington, D.C, July 08, 2025 (GLOBE NEWSWIRE) -- Today, Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) and Brain Canada announced an international partnership to advance research and transform care for people living with bipolar …
iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.
GlobeNewswire
·
July 8, 2025
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional …
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
GlobeNewswire
·
July 8, 2025
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has …
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
GlobeNewswire
·
July 8, 2025
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“ …
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
GlobeNewswire
·
July 8, 2025
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease. …
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
GlobeNewswire
·
July 8, 2025
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 …
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire
·
July 8, 2025
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
GlobeNewswire
·
July 8, 2025
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the …
Diagonal Therapeutics Appoints John Lee, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
·
July 8, 2025
Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) WATERTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- …